Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease

Minseok Seo, Weiliang Qiu, William Bailey, Gerard J. Criner, Mark T. Dransfield, Anne L. Fuhlbrigge, John J. Reilly, Mary Beth Scholand, Peter Castaldi, Robert Chase, Margaret Parker, Aabida Saferali, Jeong H. Yun, James D. Crapo, Michael H. Cho, Terri H. Beaty, Edwin K. Silverman, Craig P. Hersh

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, and long-term oxygen therapy has been shown to reduce mortality in COPD patients with severe hypoxemia. However, the Long-term Oxygen Treatment Trial (LOTT), a large randomized trial, found no benefit of oxygen therapy in COPD patients with moderate hypoxemia. We hypothesized that there may be differences in response to oxygen which depend on genotype or gene expression. In a genome-wide time-to-event analysis of the primary outcome of death or hospitalization in 331 subjects, 97 single nucleotide polymorphisms (SNPs) showed evidence of interaction with oxygen therapy at P < 1e−5, including 7 SNPs near arylsulfatase B (ARSB; P = 6e−6). In microarray expression profiling on 51 whole blood samples from 37 individuals, at screening and/or at 12-month follow-up, ARSB expression was associated with the primary outcome depending on oxygen treatment. The significant SNPs were conditional expression quantitative trait loci for ARSB expression. In a network analysis of genes affected by long-term oxygen, two observed clusters including 26 co-expressed genes were enriched in mitochondrial function. Using data from the observational COPDGene Study, we validated the expression of 25 of these 26 genes, plus ARSB. The effect of long-term oxygen therapy in COPD varied based on ARSB expression and genotype. ARSB has previously been shown to be associated with hypoxemia in human bronchial and colonic epithelial cells and in a mouse model. In peripheral blood, long-term oxygen treatment affected expression of mitochondrial-related genes, a biologically relevant pathway in COPD. SNPs and expression of ARSB are associated with response to long-term oxygen in COPD. The ARSB SNPs were expression quantitative trait loci depending on oxygen therapy. Genes differentially expressed by long-term oxygen were enriched in mitochondrial functions. This suggests a potential biomarker to personalize use of long-term oxygen in COPD.

Original languageEnglish (US)
Pages (from-to)1375-1385
Number of pages11
JournalJournal of Molecular Medicine
Issue number12
StatePublished - Dec 1 2018


  • Arylsulfatase B
  • Expression quantitative trait loci
  • Genome-wide association study
  • Microarray
  • Oxygen
  • Pharmacogenomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)


Dive into the research topics of 'Genomics and response to long-term oxygen therapy in chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this